Guardant Health announced that Craig Eagle, the company’s chief medical officer, will resign effective May 8, after stints including Roche’s Genentech and Pfizer. Delfi Diagnostics appointed Charles Newton to its board, bringing CFO and healthcare investment banking experience spanning multiple senior roles. Singular Genomics named John Stark as CEO, with a transition plan that shifts current CEO Josh Stahl to an independent director role. These moves cluster around core leadership capacity in precision oncology diagnostics and omics platforms. Eagle’s departure may influence Guardant’s medical strategy and how it supports commercialization and evidence generation. Newton’s board appointment adds governance experience from prior biotech exits, while Stark’s CEO role signals continuity in spatial biology and protein sequencing platform execution. Together, the appointments show ongoing consolidation of leadership talent across liquid biopsy, diagnostics finance, and multi-omic platform companies as they push product and clinical adoption.